{"slug":"oesophageal","tag":"oesophageal","variants":["oesophageal"],"description":"No description yet","count":4,"kinds":{"person":4},"related":[{"slug":"trialist","tag":"trialist","shared":4},{"slug":"surgery","tag":"surgery","shared":2},{"slug":"gastric","tag":"gastric","shared":1},{"slug":"immunotherapy","tag":"immunotherapy","shared":1}],"records":[{"id":"salah-eddin-al-batran","kind":"person","name":"Salah-Eddin Al-Batran","route":"/people/salah-eddin-al-batran/","tldr":"German oncologist who led FLOT4, the trial that made the FLOT chemotherapy regimen the standard before and after surgery for stomach and oesophago-gastric junction cancer."},{"id":"yuichiro-doki","kind":"person","name":"Yuichiro Doki","route":"/people/yuichiro-doki/","tldr":"Japanese surgeon who was lead author of CheckMate 648, which established nivolumab-based first-line treatment for advanced oesophageal squamous-cell carcinoma."},{"id":"jong-mu-sun","kind":"person","name":"Jong-Mu Sun","route":"/people/jong-mu-sun/","tldr":"Korean oncologist who was lead author of KEYNOTE-590, the trial that added pembrolizumab to first-line chemotherapy for advanced oesophageal cancer."},{"id":"jens-hoeppner","kind":"person","name":"Jens Höppner","route":"/people/jens-hoeppner/","tldr":"German surgeon who led ESOPEC, the trial that compared FLOT chemotherapy with CROSS chemoradiotherapy before surgery for oesophageal adenocarcinoma and found FLOT gave longer survival."}]}